Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Table 6 Overall survival and progression-free survival from the start of second-line targeted therapy according to progression-free survival on first-line targeted therapy

Second-line targeted therapy	n	OS		PFS
Second-line targeted therapy	n	Median (95% CI)	P	Median (95% CI)	P
Everolimus
PFS1 < 9 months	230	12.7 months (10.5–14.9)	< 0.001	5.0 months (3.9–6.1)	< 0.001
PFS1 ≥ 9 months	290	19.7 months (16.4–23.0)	< 0.001	7.3 months (5.9–8.8)	< 0.001
Sorafenib
PFS1 < 9 months	123	13.8 months (7.9–19.7)	0.083	5.4 months (4.1–6.7)	0.628
PFS1 ≥ 9 months	117	17.5 months (14.6–20.4)	0.083	6.2 months (5.0–7.4)	0.628
Sunitinib
PFS1 < 9 months	136	12.9 months (5.7–20.1)	0.171	5.0 months (4.0–6.0)	0.571
PFS1 ≥ 9 months	92	15.7 months (9.5–22.0)	0.171	6.9 months (4.0–9.7)	0.571

95% CI 95% confidence interval, OS overall survival, PFS progression-free survival, PFS1 progression-free survival on first-line targeted therapy

ISSN: 1471-2407